BioMarin Kills Development Of Duchenne Muscular Dystrophy Treatment
The company was deterred by regulatory roadblocks it encountered in its efforts to get the experimental drug approved. In other news, drugmaker Grifols S.A. is entering a partnership with diagnostics company Singulex Inc.
San Francisco Business Times:
BioMarin's $700M Bet Becomes 'Sucker Punch' For Rare Disease Patients
BioMarin Pharmaceutical Inc. killed development of an experimental treatment for a rare muscle-weakening disease and a trio of potential follow-on drugs, the company said Tuesday, dealing a blow to patients and advocates pressing for FDA approval of a therapy. (Leuty, 5/31)
San Francisco Business Times:
Big East Bay Drug Company Buys Into Small East Bay Diagnostic Company
Spanish drug and diagnostics maker Grifols S.A. will spend $50 million for a 20 percent stake in diagnostics company Singulex Inc. and an exclusive worldwide license for the Alameda company's technology for screening donor blood and plasma. (Leuty, 5/31)